Calendario›IPHA›Anti-KIR
Anti-KIR
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Ensayo de Innate Pharma SA en Mieloma multiple.
Más ensayos de: Mieloma múltiple.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 32
- Centros
- 4
- Fin del objetivo primario
- ene 2011
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en may 2007.
Qué mide
Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment (From start of the treatment to end of study) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroDevelopment of new treatments for diseases such as multiple myeloma is a focus for research. The research being conducted is on treatment called Anti-KIR (1-7F9), which activates the body's own cells to kill tumor cells. This is different from many other treatments where chemicals are given to kill tumor cells. The purpose of the study is to determine a safe dose of Anti-KIR (1-7F9) to administer in humans and to gain information about its effectiveness in the treatment of multiple myeloma.
Más ensayos de IPHA
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| IPH5201 + durvalumab + standard… | Fase 2 | Reclutando pacientes | jun 2027 (prevista) |
| IPH4502 | Fase 1 | En marcha, sin reclutar | abr 2028 (prevista) |
| IPH6501 | Fase 1/2 | Interrumpido | feb 2026 (real) |
| IPH4102 · TELLOMAK | Fase 2 | Completado | ene 2026 (real) |
| lacutamab | Fase 1 | Completado | nov 2023 (real) |
| Monalizumab | Fase 1/2 | Completado | mar 2023 (real) |
Todos los de IPHA, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT00552396), actualizada en mar 2016.